In Q1'26, UnitedHealth Group's (UNH) operating expenses totaled $15.39B USD, entirely comprising SG&A expenses, as R&D expenses remained at no data across all periods. This latest figure reflects a decline from the Q4'25 peak of $16.99B USD, indicating a moderation in expense growth following a strong upward trajectory in the latter half of FY2025. Over the period from Q2'23 to Q1'26, SG&A expenses exhibited overall stability with moderate fluctuations, starting at $13.81B USD and ranging between $12.49B USD (Q4'24 low) and $16.99B USD (Q4'25 high), driven by a notable 28% year-over-year surge from Q3'24 to Q3'25 before the recent pullback. R&D expenses showed no data throughout, suggesting this category is not applicable or reportable for UNH's operations in a stacked bar chart format. The trend highlights controlled cost management amid seasonal variations, with total operating expenses mirroring SG&A patterns and averaging approximately $14.2B USD quarterly.